Healthcare provider profile · identity verified

Rupal V. Amin, M.D.

Internal Medicine · AMES, IA · NPI 1225024995

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	689	128
Atorvastatin Calcium	Atorvastatin Calcium	410	104
Losartan Potassium	Losartan Potassium	341	83
Omeprazole	Omeprazole	336	86
Amlodipine Besylate	Amlodipine Besylate	301	76
Metoprolol Succinate	Metoprolol Succinate	291	61
Rosuvastatin Calcium	Rosuvastatin Calcium	272	69
Gabapentin	Gabapentin	268	66
Lisinopril	Lisinopril	248	65
Eliquis	Apixaban	238	30
Simvastatin	Simvastatin	220	51
Furosemide	Furosemide	194	43
Tramadol Hcl	Tramadol Hcl	171	43
Duloxetine Hcl	Duloxetine Hcl	168	34
Pantoprazole Sodium	Pantoprazole Sodium	156	34
Trazodone Hcl	Trazodone Hcl	108	34
Potassium Chloride	Potassium Chloride	98	30
Hydrochlorothiazide	Hydrochlorothiazide	96	30
Sertraline Hcl	Sertraline Hcl	90	23
Escitalopram Oxalate	Escitalopram Oxalate	87	24
Spironolactone	Spironolactone	74	15
Ozempic	Semaglutide	67	13
Clopidogrel	Clopidogrel Bisulfate	61	13
Metoprolol Tartrate	Metoprolol Tartrate	60	12
Jardiance	Empagliflozin	58	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	13
Alendronate Sodium	Alendronate Sodium	56	17
Donepezil Hcl	Donepezil Hcl	55	suppressed
Montelukast Sodium	Montelukast Sodium	51	18
Buspirone Hcl	Buspirone Hcl	50	11
Citalopram Hbr	Citalopram Hydrobromide	49	16
Paroxetine Hcl	Paroxetine Hcl	49	suppressed
Bupropion Xl	Bupropion Hcl	47	13
Metformin Hcl	Metformin Hcl	47	13
Pravastatin Sodium	Pravastatin Sodium	47	15
Tamsulosin Hcl	Tamsulosin Hcl	45	13
Estradiol	Estradiol	44	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	13
Baclofen	Baclofen	43	17
Clonidine Hcl	Clonidine Hcl	42	suppressed
Synthroid	Levothyroxine Sodium	42	suppressed
Ropinirole Hcl	Ropinirole Hcl	40	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	suppressed
Memantine Hcl	Memantine Hcl	39	suppressed
Glimepiride	Glimepiride	37	suppressed
Cephalexin	Cephalexin	36	31
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Hydralazine Hcl	Hydralazine Hcl	35	suppressed
Metformin Hcl Er	Metformin Hcl	35	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	35	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	16
Novolog Flexpen	Insulin Aspart	32	suppressed
Warfarin Sodium	Warfarin Sodium	32	suppressed
Allopurinol	Allopurinol	31	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	14
Trulicity	Dulaglutide	30	suppressed
Xarelto	Rivaroxaban	30	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	28	suppressed
Mupirocin	Mupirocin	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Primidone	Primidone	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	23	14
Ketoconazole	Ketoconazole	23	14
Lactulose	Lactulose	23	suppressed
Levetiracetam	Levetiracetam	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Ramipril	Ramipril	22	suppressed
Verapamil Er	Verapamil Hcl	22	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	21	suppressed
Lorazepam	Lorazepam	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	suppressed
Trospium Chloride	Trospium Chloride	21	suppressed
Carvedilol	Carvedilol	20	suppressed
Latanoprost	Latanoprost	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Felodipine Er	Felodipine	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	16
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	17	13
Colestipol Hcl	Colestipol Hcl	17	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	17	suppressed
Rivastigmine	Rivastigmine Tartrate	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	14
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Fenofibrate	Fenofibrate,micronized	15	suppressed
Fentanyl	Fentanyl	15	suppressed
Tresiba Flextouch U-200	Insulin Degludec	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	11
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Bydureon Bcise	Exenatide Microspheres	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Potassium Citrate Er	Potassium Citrate	13	suppressed
Topiramate	Topiramate	13	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Metaxalone	Metaxalone	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Fosfomycin Tromethamine	Fosfomycin Tromethamine	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Rocklatan	Netarsudil Mesylat/Latanoprost	11	suppressed
Zenpep	Lipase/Protease/Amylase	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error